Form a of fluoxetine hydrochloride

Details Form a of fluoxetine hydrochloride Form a of fluoxetine hydrochloride

2001-01-31

2001-11-13

Barts, Samuel (Department: 1621)

Organic compounds -- part of the class 532-570 series

Organic compounds

Amino nitrogen containing

C514S651000

Reexamination Certificate

active

06316672

ABSTRACT:

The present invention is generally concerned with a novel polymorphic form of fluoxetine hydrochloride, (±)-N-methyl-3-phenyl-2- [&agr;,&agr;,&agr;- trifluoro-p-tolyl)oxy]propylamine hydrochloride, which is marketed by Dista Products and Eli Lilly and Company (the “Innovator”), Indianapolis, Ind., under the trade name Prozac®. The present invention is further concerned with the preparation and use of the polymorphic form of fluoxetine hydrochloride now designated Form A (“Form A”).
Polymorphic forms of the same drug substance (also known as the active pharmaceutical ingredient or “API”), as administered by itself or formulated as a drug product (also known as the final or finished dosage form) are well known in the pharmaceutical art to affect, for example, the solubility, stability, flowability, fractability, and compressibility of drug substances and the safety and efficacy of drug products, (see, e.g. Knapman, K
Modern Drug Discoveries,
March, 2000: 53). So critical are the potential effects of different polymorphic forms in a single drug substance on the safety and efficacy of the respective drug product(s) that the United States Food and Drug Administration (the “FDA”) requires each drug substance manufacturer, in the least, to control its synthetic processes such that the percentages of the various respective polymorphic forms, when present, must be consistent among batches and within the drug substance/product's specification as approved by the FDA.
Left uncontrolled in synthetic processes, the percentage of a given polymorph outside of an FDA approved specification would render the adulterated batches unfit for commercial sale. Accordingly, the FDA requires fill characterization of each drug substance used in each drug product marketed in the United States, including the identification and control of polymorphic forms. The FDA further requires robust synthetic process specifications and controls which consistently produce the respective drug substance and drug product.
Unfortunately, the detection of various polymorphic forms of a single drug substance is not always readily discernable by pharmaceutical chemists. Such a drug substance would not be manufactured with appropriate controls, potentially leaving the attendant safety and efficacy risks unaddressed.
It has been discovered that fluoxetine hydrochloride drug substance, generally used to prepare Prozac® and potential generic drugs thereto (fluoxetine hydrochloride API), has not been fully or completely characterized. It has been unexpectedly discovered that such fluoxetine hydrochloride API drug substance comprises at least three crystalline forms, which occur at varying and uncontrolled ratios from batch to batch. These three identified polymorphs have been designated Form A, Form B, and Form C, correlated to the relative proportion of each polymorph in fluoxetine hydrochloride, from greatest to least.
It has further been discovered that Form A can be prepared in pure or essentially pure polymorphic form in robust, controllable, synthetic processes.


REFERENCES:
patent: 4296126 (1981-10-01), Nedelac et al.
patent: 4314081 (1982-02-01), Molloy et al.
patent: 4584404 (1986-04-01), Molloy et al.
patent: 4626549 (1986-12-01), Molloy et al.
patent: 5068432 (1991-11-01), Brown
patent: 5104899 (1992-04-01), Young et al.
patent: 5166437 (1992-11-01), Kairisalo et al.
patent: 5225585 (1993-07-01), Schwartz et al.
patent: 5238959 (1993-08-01), Robertson et al.
patent: 5250571 (1993-10-01), Fuller et al.
patent: 5589511 (1996-12-01), Young et al.
patent: 5618968 (1997-04-01), Crnic et al.
patent: 5648396 (1997-07-01), Young et al.
patent: 5708035 (1998-01-01), Young et al.
patent: 5847214 (1998-12-01), Arosio et al.
patent: 5936124 (1999-08-01), Hilborn et al.
patent: 6025517 (2000-02-01), Hilborn et al.
patent: 6028224 (2000-02-01), Hilborn et al.
patent: 0 529 842 B1 (1996-04-01), None
patent: 0 391 070 B1 (1994-01-01), None
patent: 2060618 (1981-05-01), None
patent: WO99/49857 (1999-10-01), None
patent: WO98/11054 (1998-03-01), None
patent: WO94/00416 (1994-01-01), None

Affiliated with

Also associated with

Rating

Form a of fluoxetine hydrochloride does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Form a of fluoxetine hydrochloride, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Form a of fluoxetine hydrochloride will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2607720